Jan 08, 2024 / 06:30PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Gilead today. From the company, we're going to have a presentation from Dan O'Day, Chairman and CEO. And following the presentation, we'll jump into a Q&A session with Dan and the broader management team. So with that, Dan, Happy New Year. Thanks for joining us, and over to you.
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Thanks, Chris. Delighted to be here. Thank you for hosting us. Good morning, everybody. Delighted to have a chance to communicate with all of you this morning. I've got a great team up here, too, that can get into questions and answers with you as well. We're off to a really good start this year.
Let me just say that I think this is an incredibly important year for the company in 2024. I'll get into it. But the build that we've been doing over the past 4 years is really coming to fruition.
We more than doubled
Gilead Sciences Inc at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers